Erudio Healtherudio.com
Sponsor
National Cancer Institute (NCI) trials: what clinicians said in public
HCP commentary reports on 2 clinical trials sponsored by National Cancer Institute (NCI): A041703 and EA3191. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 81 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (National Cancer Institute (NCI)). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| A041703 NCT03739814 · National Cancer Institute (NCI) | CD22-positive B-lineage acute lymphoblastic leukemia | Phase 2 | 133 | 23 | Focused | Nov 9, 2026 | Preview |
| EA3191 NCT04671667 · National Cancer Institute (NCI) | recurrent head and neck squamous cell carcinoma | Phase 2 | 98 | 12 | Focused | Oct 17, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| S1826 NCT03907488 · National Cancer Institute (NCI) DeepView → | newly diagnosed advanced-stage classical Hodgkin lymphoma | Phase 3 | Deep | View | |||
| TAILORx NCT00310180 · National Cancer Institute (NCI) DeepView → | hormone receptor-positive HER2-negative node-negative breast cancer | Phase 3 | Deep | View | |||
| RxPONDER NCT01272037 · National Cancer Institute (NCI) DeepView → | Not given | Phase 3 | Deep | View | |||
| NRG-LU005 NCT03811002 · National Cancer Institute (NCI) DeepView → | limited-stage small cell lung cancer | Phase 3 | Deep | View | |||
| S1801 NCT03698019 · National Cancer Institute (NCI) DeepView → | clinically detectable stage III-IV high-risk melanoma | Phase 2 | Deep | View | |||
| PAPMET2 NCT05411081 · National Cancer Institute (NCI) DeepView → | advanced papillary renal cell carcinoma | Phase 2 | Deep | View | |||
| NRG-GY018 NCT03914612 · National Cancer Institute (NCI) DeepView → | stage III-IV or recurrent endometrial cancer | Phase 3 | Deep | View | |||
| MAIN-CAV NCT05092958 · National Cancer Institute (NCI) DeepView → | metastatic urothelial cancer | Phase 3 | Deep | View | |||
| E3A06 NCT01169337 · National Cancer Institute (NCI) DeepView → | asymptomatic high-risk smoldering multiple myeloma | Phase 3 | Deep | View | |||
| E4A03 NCT00098475 · National Cancer Institute (NCI) DeepView → | newly diagnosed multiple myeloma | Phase 3 | Deep | View | |||
| E1910 NCT02003222 · National Cancer Institute (NCI) DeepView → | newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia | Phase 3 | Deep | View | |||
| EA5181 NCT04092283 · National Cancer Institute (NCI) DeepView → | unresectable stage III non-small cell lung cancer | Phase 3 | Deep | View | |||
| CABOSUN NCT01835158 · National Cancer Institute (NCI) DeepView → | previously untreated advanced clear cell renal cell carcinoma | Phase 2 | Deep | View | |||
| ATOMIC NCT02912559 · National Cancer Institute (NCI) DeepView → | stage III mismatch repair-deficient colon cancer | Phase 3 | Deep | View | |||
| RTOG 0848 NCT01013649 · National Cancer Institute (NCI) DeepView → | resected pancreatic head adenocarcinoma | Phase 3 | Deep | View | |||
| INSIGNA NCT03793179 · National Cancer Institute (NCI) DeepView → | advanced nonsquamous non-small cell lung cancer | Phase 3 | Deep | View | |||
| E1912 NCT02048813 · National Cancer Institute (NCI) DeepView → | untreated chronic lymphocytic leukemia or small lymphocytic lymphoma | Phase 3 | Deep | View | |||
| S0777 NCT00644228 · National Cancer Institute (NCI) DeepView → | previously untreated multiple myeloma | Phase 3 | Deep | View | |||
| PAPMET NCT02761057 · National Cancer Institute (NCI) DeepView → | advanced papillary renal cell carcinoma | Phase 2 | Deep | View | |||
| S1806 NCT03775265 · National Cancer Institute (NCI) DeepView → | localized muscle invasive bladder cancer | Phase 3 | Deep | View | |||
| PROSPER RCC NCT03055013 · National Cancer Institute (NCI) DeepView → | localized renal cell carcinoma | Phase 3 | Deep | View | |||
| AALL1731 NCT03914625 · National Cancer Institute (NCI) DeepView → | newly diagnosed standard-risk B-cell acute lymphoblastic leukemia | Phase 3 | Deep | View | |||
| NRG-GI002 NCT02921256 · National Cancer Institute (NCI) DeepView → | locally advanced rectal cancer | Phase 2 | Deep | View | |||
| ANVIL NCT02595944 · National Cancer Institute (NCI) DeepView → | resected stage IB-IIIA non-small cell lung cancer | Phase 3 | Deep | View | |||
| NRG-HN005 NCT03952585 · National Cancer Institute (NCI) DeepView → | early-stage HPV-positive non-smoking associated oropharyngeal cancer | Phase 2/Phase 3 | Deep | View | |||
| AHOD2131 NCT05675410 · National Cancer Institute (NCI) DeepView → | newly diagnosed stage I/II classic Hodgkin lymphoma | Phase 3 | Deep | View | |||
| AMBASSADOR NCT03244384 · National Cancer Institute (NCI) DeepView → | muscle-invasive and locally advanced urothelial carcinoma | Phase 3 | Deep | View | |||
| CALGB 40603 NCT00861705 · National Cancer Institute (NCI) DeepView → | stage II to III triple-negative breast cancer | Phase 2 | Deep | View | |||
| EA2201 NCT04751370 · National Cancer Institute (NCI) DeepView → | MSI-H/dMMR locally advanced rectal adenocarcinoma | Phase 2 | Deep | View | |||
| NCT03793166 NCT03793166 · National Cancer Institute (NCI) StandardView → | Not given | Phase 3 | Standard | View | |||
| SWOG 2107 NCT05308446 · National Cancer Institute (NCI) StandardView → | previously treated microsatellite stable BRAFV600E metastatic colorectal cancer | Phase 2 | Standard | View | |||
| CALGB 90601 NCT00942331 · National Cancer Institute (NCI) StandardView → | advanced urothelial carcinoma | Phase 3 | Standard | View | |||
| AHOD1331 NCT02166463 · National Cancer Institute (NCI) StandardView → | newly diagnosed high-risk pediatric classical Hodgkin lymphoma | Phase 3 | Standard | View | |||
| NCI9673 NCT02314169 · National Cancer Institute (NCI) StandardView → | refractory metastatic anal canal squamous cell carcinoma | Phase 2 | Standard | View | |||
| SWOG S1609 NCT02834013 · National Cancer Institute (NCI) StandardView → | rare tumors | Phase 2 | Standard | View | |||
| SWOG S1605 NCT02844816 · National Cancer Institute (NCI) StandardView → | BCG-unresponsive high-risk non-muscle-invasive bladder cancer | Phase 2 | Standard | View | |||
| SWOG S1914 NCT04214262 · National Cancer Institute (NCI) StandardView → | high-risk early-stage non-small-cell lung cancer | Phase 3 | Standard | View | |||
| A041202 NCT01886872 · National Cancer Institute (NCI) StandardView → | previously untreated chronic lymphocytic leukemia in older patients | Phase 3 | Standard | View | |||
| EA2165 NCT03233711 · National Cancer Institute (NCI) StandardView → | high risk stage II-IIIB anal cancer | Phase 3 | Standard | View | |||
| ETCTN 10388 NCT04234568 · National Cancer Institute (NCI) StandardView → | well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors | Phase 1 | Standard | View | |||
| NRG-HN004 NCT03258554 · National Cancer Institute (NCI) StandardView → | Not given | Phase 2/Phase 3 | Standard | View | |||
| ARCHON-1 NCT03801902 · National Cancer Institute (NCI) StandardView → | PD-L1 high locally advanced non-small cell lung cancer | Phase 1 | Standard | View | |||
| OPTIMUM NCT03941860 · National Cancer Institute (NCI) StandardView → | residual multiple myeloma | Phase 3 | Standard | View | |||
| SWOG S2001 NCT04548752 · National Cancer Institute (NCI) StandardView → | metastatic pancreatic cancer with germline BRCA1/2 mutations | Phase 2 | Standard | View | |||
| NCT05112601 NCT05112601 · National Cancer Institute (NCI) StandardView → | dMMR recurrent endometrial carcinoma | Phase 2 | Standard | View | |||
| S2308 NCT06337318 · National Cancer Institute (NCI) StandardView → | low tumor burden follicular lymphoma | Phase 3 | Standard | View | |||
| PARRC NCT06770582 · National Cancer Institute (NCI) StandardView → | high-grade T1 bladder cancer | Phase 2 | Standard | View | |||
| NRG-GY017 NCT03738228 · National Cancer Institute (NCI) FocusedView → | node-positive locally advanced cervical cancer | Phase 1 | Focused | View | |||
| NCT01572480 NCT01572480 · National Cancer Institute (NCI) FocusedView → | high-risk smoldering multiple myeloma | Phase 2 | Focused | View | |||
| EAA172 NCT03701321 · National Cancer Institute (NCI) FocusedView → | relapsed or refractory multiple myeloma | Phase 1/Phase 2 | Focused | View | |||
| NRG-GY026 NCT05256225 · National Cancer Institute (NCI) FocusedView → | HER2-positive endometrial serous carcinoma or carcinosarcoma | Phase 3 | Focused | View | |||
| NRG-GY035 NCT07198074 · National Cancer Institute (NCI) FocusedView → | pMMR, TP53-mutated advanced or recurrent endometrial cancer | Phase 3 | Focused | View | |||
| RADICAL NCT04071223 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 2 | Focused | View | |||
| EAA232 NCT06948084 · National Cancer Institute (NCI) FocusedView → | high-risk multiple myeloma refractory or in first relapse | Phase 2 | Focused | View | |||
| RTOG-1106 NCT01507428 · National Cancer Institute (NCI) FocusedView → | stage III non-small cell lung cancer | Phase 2 | Focused | View | |||
| NCT02193282 NCT02193282 · National Cancer Institute (NCI) FocusedView → | resected stage IB-IIIA EGFR-mutant non-small cell lung cancer | Phase 3 | Focused | View | |||
| CABINET NCT03375320 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 3 | Focused | View | |||
| ETCTN 10166 NCT03600701 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 2 | Focused | View | |||
| INSPIRE NCT04216290 · National Cancer Institute (NCI) FocusedView → | stage III node-positive bladder urothelial carcinoma | Phase 2 | Focused | View | |||
| ALCHEMIST Chemo-IO NCT04267848 · National Cancer Institute (NCI) FocusedView → | resected stage II–IIIB non-small cell lung cancer | Phase 3 | Focused | View | |||
| E-VIRTUE NCT06041503 · National Cancer Institute (NCI) FocusedView → | rare genitourinary tumors | Phase 2 | Focused | View | |||
| AALL0434 NCT00408005 · National Cancer Institute (NCI) FocusedView → | newly diagnosed T-cell acute lymphoblastic leukemia or lymphoma | Phase 3 | Focused | View | |||
| NCT02997228 NCT02997228 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 3 | Focused | View | |||
| A041702 NCT03737981 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCI-NRG ALK Protocol NCT03737994 · National Cancer Institute (NCI) FocusedView → | previously treated ALK-positive stage IV non-squamous NSCLC | Phase 2 | Focused | View | |||
| NCT03984448 NCT03984448 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||
| MODERN NCT05987241 · National Cancer Institute (NCI) FocusedView → | muscle-invasive urothelial carcinoma | Phase 2/Phase 3 | Focused | View | |||
| ECOG-ACRIN EA8231 NCT06524544 · National Cancer Institute (NCI) FocusedView → | anti-PD(L)1-resistant advanced urothelial cancer | Phase 3 | Focused | View | |||
| NCT06661915 NCT06661915 · National Cancer Institute (NCI) FocusedView → | accelerated/blast-phase Philadelphia chromosome-negative myeloproliferative neoplasms | Phase 2 | Focused | View | |||
| NCT02496208 NCT02496208 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 1 | Focused | View | |||
| ICONIC NCT03866382 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 2 | Focused | View | |||
| MyeloMATCH NCT06577441 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 2 | Focused | View | |||
| CALGB 80802 NCT01015833 · National Cancer Institute (NCI) FocusedView → | advanced hepatocellular carcinoma | Phase 3 | Focused | View | |||
| NCT02484404 NCT02484404 · National Cancer Institute (NCI) FocusedView → | advanced solid tumors | Phase 1/Phase 2 | Focused | View | |||
| NCT02933255 NCT02933255 · National Cancer Institute (NCI) FocusedView → | prostate cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT03076554 NCT03076554 · National Cancer Institute (NCI) FocusedView → | thymoma and thymic carcinoma after platinum-based chemotherapy | Phase 2 | Focused | View | |||
| NCT04206319 NCT04206319 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 2 | Focused | View | |||
| S1929 NCT04334941 · National Cancer Institute (NCI) FocusedView → | SLFN11-positive extensive-stage small cell lung cancer | Phase 2 | Focused | View | |||
| NCT04417660 NCT04417660 · National Cancer Institute (NCI) FocusedView → | thymoma and thymic carcinoma | Phase 2 | Focused | View | |||
| NCT05104736 NCT05104736 · National Cancer Institute (NCI) FocusedView → | thymoma and thymic carcinoma | Phase 2 | Focused | View | |||
| AALL2131 NCT06124157 · National Cancer Institute (NCI) FocusedView → | Ph+ or ABL-class Ph-like B-cell acute lymphoblastic leukemia | Phase 2 | Focused | View | |||